StockData
ProMIS Neurosciences Inc. logo

ProMIS Neurosciences Inc. (PMN) stock

PMNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$3.13−0.08 (-2.49%)

Close on Nov 18, 2026Market cap $28.07MP/E –Yield –

ProMIS Neurosciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

ProMIS Neurosciences's operating income for the twelve months ending Jun 30, 2026 was -$43.43M. For fiscal 2025 it was -$40.17M. The highest annual figure on record is -$8.29M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$40.17M–
FY2024Dec 31, 2024-$16.83M–
FY2023Dec 31, 2023-$14.26M–
FY2022Dec 31, 2022-$23.38M–
FY2021Dec 31, 2021-$8.29M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$12.27M–
Q1 FY2026Mar 31, 2026-$8.64M–
Q4 FY2025Dec 31, 2025-$10.77M–
Q3 FY2025Sep 30, 2025-$11.75M–
Q2 FY2025Jun 30, 2025-$10.18M–
Q1 FY2025Mar 31, 2025-$7.46M–
Q4 FY2024Dec 31, 2024-$6.00M–
Q3 FY2024Sep 30, 2024-$4.43M–
Q2 FY2024Jun 30, 2024-$2.71M–
Q1 FY2024Mar 31, 2024-$3.68M–
Q4 FY2023Dec 31, 2023-$3.87M–
Q3 FY2023Sep 30, 2023-$2.52M–
Q2 FY2023Jun 30, 2023-$2.90M–
Q1 FY2023Mar 31, 2023-$4.97M–
Q4 FY2022Dec 31, 2022-$8.52M–
Q3 FY2022Sep 30, 2022-$6.05M–
Q2 FY2022Jun 30, 2022-$4.86M–
Q1 FY2022Mar 31, 2022-$3.94M–
Q4 FY2021Dec 31, 2021-$4.55M–
Q3 FY2021Sep 30, 2021-$2.07M–
Q2 FY2021Jun 30, 2021-$1.11M–

More ProMIS Neurosciences figures

See a number that looks wrong?